

IN THE CLAIMS

Please amend the claims as follows:


Claims 13-36: Canceled

37. (New, Corresponds to Claim 16) N-[(4-ethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medically acceptable salt or hydrate thereof.

38. (New, Corresponds to Claim 17) N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medically acceptable salt or hydrate thereof.

39. (New, Corresponds to Claim 18) N-[(2,4-dichlorophenyl)-methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medically acceptable salt or hydrate thereof.

40. (New, Corresponds to Claim 19) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, comprising a substituted benzylthiazolidine-2,4-dione derivative represented by the formula (1):



wherein

either

R^1 denotes a 4-chloro, 3-trifluoromethyl, or 4-ethoxy substituent, and

R^2 denotes a hydrogen atom,

or

R^1 denotes a 4-chloro substituent, and

R^2 denotes a 2-chloro substituent,

or a medically acceptable salt or hydrate thereof.

41. (New, Corresponds to Claim 20) The tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 40, wherein R^1 denotes a 4-chloro, 3-trifluoromethyl, or 4-ethoxy substituent, and R^2 denotes a hydrogen atom, or a medically acceptable salt or hydrate thereof.

42. (New, Corresponds to Claim 21) The tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 40, wherein the substituted benzylthiazolidine-2,4-dione derivative is N-[(3-trifluoromethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medically acceptable salt or hydrate thereof.

43. (New, Corresponds to Claim 22) The tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 40, wherein the substituted benzylthiazolidine-2,4-dione derivative is N-[(4-ethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medically acceptable salt or hydrate thereof.

44. (New, Corresponds to Claim 23) The tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, wherein the substituted benzylthiazolidine-2,4-dione derivative is N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medically acceptable salt or hydrate thereof.

45. (New, Corresponds to Claim 24) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, wherein the substituted benzylthiazolidine-2,4-dione derivative is N-[(2,4-dichlorophenyl)-methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medically acceptable salt or hydrate thereof.

46. (New, Corresponds to Claim 31) A method of reducing blood glucose, comprising administering an effective amount of N-[(4-ethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medically acceptable salt or hydrate thereof to a subject in need thereof.

47. (New, Corresponds to Claim 32) A method of treating hyperlipidemia, comprising administering an effective amount of N-[(4-ethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medically acceptable salt or hydrate thereof to a subject in need thereof.

48. (New, Corresponds to Claim 33) A method of reducing blood glucose, comprising administering an effective amount of N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medically acceptable salt or hydrate thereof to a subject in need thereof.

49. (New, Corresponds to Claim 34) A method of treating hyperlipidemia, comprising administering an effective amount of N-[(4-chlorophenyl)methyl]-5-[(2,4-

dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medicinally acceptable salt or hydrate thereof to a subject in need thereof.

50. (New, Corresponds to Claim 35) A method of reducing blood glucose, comprising administering an effective amount of N-[(2,4-dichlorophenyl)-methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medicinally acceptable salt or hydrate thereof to a subject in need thereof.

51. (New, Corresponds to Claim 36) A method of treating hyperlipidemia, comprising administering an effective amount of N-[(2,4-dichlorophenyl)-methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide or a medicinally acceptable salt or hydrate thereof to a subject in need thereof.

52. (New) A method of reducing blood glucose, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 40 to a subject in need thereof.

53. (New) A method of reducing blood glucose, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 41 to a subject in need thereof.

54. (New) A method of reducing blood glucose, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 42 to a subject in need thereof.

55. (New) A method of reducing blood glucose, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 43 to a subject in need thereof.

56. (New) A method of reducing blood glucose, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 44 to a subject in need thereof.

57. (New) A method of reducing blood glucose, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 45 to a subject in need thereof.

58. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 40 to a subject in need thereof.

59. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 41 to a subject in need thereof.

60. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 42 to a subject in need thereof.

61. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 43 to a subject in need thereof.

62. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 44 to a subject in need thereof.

Application No. 10/049,937
Reply to Office Action of March 31, 2003

63. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository of Claim 45 to a subject in need thereof.

Application No. 10/049,937
Reply to Office Action of March 31, 2003

SUPPORT FOR THE AMENDMENTS

Newly added Claims 37-63 are supported by the specification at pages 4-11, especially the Examples, and by original Claims 1-12. No new matter is believed to have been added to this application by these amendments.